

## Emyria selected to join Palantir's Foundry Builders Program

### Highlights:

- Emyria invited to join cohort of emerging companies participating in Palantir's Foundry Builders program
- Palantir Technologies (NYSE:PLTR, market cap: US\$54B), co-founded by Peter Thiel (PayPal), is a world leader in data platforms for major organisations and institutions with complex and sensitive data environments including the FDA, National Institutes of Health and Sanofi
- The Palantir Foundry Builders program was established to allow select companies access to powerful and highly secure data integration and analysis software typically only available to major enterprises
- Under the program, Emyria will have access to the full Palantir Foundry stack, greatly enhancing Emyria's data infrastructure, security, integration, and analysis capabilities
- Palantir Foundry will now form the backbone of Emyria's proprietary Real-World Evidence asset, as well as accelerate Emyria's data-guided drug development programs targeting FDA and TGA registrations

**Emyria Limited (ASX: EMD)** (Emyria or the Company) - a data-backed clinical drug development and care delivery company focused on accelerating treatment development and improving patient care - is pleased to announce it has been invited to participate in the second cohort of Palantir's Foundry Builders Program.

Under Foundry for Builders [4], Palantir provides Foundry to emerging companies connected to Palantir alumni under a markedly reduced subscription model. Emyria's CEO, Dr Michael Winlo, previously worked with Palantir in their health data team in San Francisco.

The Palantir Foundry platform transforms the way organisations operate by creating a central operating system for their data. Palantir Foundry is designed to scale with increasing complexity, meaning it can support companies as they grow while powering data-driven decision-making.

# emyria

**Emyria's Managing Director, Dr. Michael Winlo**, said: "We're delighted to be selected to be part of the global Palantir ecosystem and leveraging one of the world's most sophisticated and powered data platforms for our proprietary Real-World Evidence.

*Real World Evidence (RWE) is being increasingly used by major global drug regulators, like the FDA, to evaluate the safety and efficacy of new treatments.*

*Palantir Foundry greatly improves our ability to secure, integrate, generate and analyse our Real World Evidence - both internally and with our global partners - meaning we can deliver on our mission to develop new treatments and improve patient care, faster.*

*By using Palantir Foundry, we can generate dose-response insights and clinical decision support tools using advanced statistical and machine learning algorithms. We are also able to capture all relevant intellectual property related to our research while securely protecting patient privacy.*

## **Emyria's Real World Evidence**

Emyria's growing RWE asset (**Emyria Data**) now covers detailed and longitudinal health outcome data for more than 5,000 patients with complex medical conditions and receiving unregistered treatments. Emyria's RWE provides unique dose-response insights and intellectual property that supports Emyria's active and developing drug development programs (**Emyria Treatments**).

RWE is also being increasingly used in the evaluation of new drug registrations by major global regulators like the FDA.

## **Palantir supports use of RWE according to recent FDA guidance**

The FDA recently released a guidance document called "*The FDA Real-World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision-Making for Drug and Biological Products*" [5]

This guidance highlighted the importance of ensuring all data used to generate RWE has the highest standards of data **accuracy, completeness**, provenance, and **traceability**.

## **Palantir impact in healthcare today**

Notable users of Palantir Foundry:

- **FDA:** Palantir's partnership with the FDA provides an enterprise data management and analytics solution for the Center for Drug Evaluation and Research (CDER) and the Oncology Center of Excellence (OCE), amongst their other technology investments.[1]
  - **Sanofi:** Palantir's partnership with Sanofi provides core data infrastructure and an
-

# emyria

analytical platform as part of their platform for RWE research, receiving a 2020 Gartner Healthcare and Life Sciences Eye on Innovation Award for this work.[2]

A copy of Palantir's announcement attached. This announcement has been approved and authorised for release by the Managing Director of Emyria Limited.

For further information:

**Dr. Michael Winlo**  
**Managing Director**  
**1300 436 363**

[mwinlo@emyria.com](mailto:mwinlo@emyria.com)

**Lexi O'Halloran**  
**Media/Investor Relations**  
**+ 61 (0) 404 577 076**

[lexi@janemorganmanagement.com.au](mailto:lexi@janemorganmanagement.com.au)

**Andrew Williams**  
**Media Relations**  
**+61 (0) 412 614 125**

[andrew@profilemedia.com.au](mailto:andrew@profilemedia.com.au)

## References:

- [1] <https://www.businesswire.com/news/home/20201208005711/en/Palantir-Technologies-Expands-FDA-Partnership-With-44m-Contract>
- [2] [Healthcare Impact Studies](#)
- [3] <https://www.palantir.com/impact/rwe-pharma-san/> [4]
- [4] <https://www.palantir.com/offerings/foundry-for-builders/>
- [5] <https://www.fda.gov/media/152503/download>

---

## About Emyria ([www.emyria.com](http://www.emyria.com))

Emyria Limited is a clinical drug development and care delivery company focused on accelerating drug development and improving patient care.

**Emyria's Treatments** target large unmet needs and are focused on obtaining approval ("registration") with major global regulators. Emyria's treatment development programs are informed by insights generated from extensive analysis of **Emyria Data** - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria's independent clinical services (**Emerald Clinics** - [www.emeraldclinics.com.au](http://www.emeraldclinics.com.au))

**Emyria Data** provides deep treatment insights and is, therefore, a source of unique IP, strategically designed drug development, and personalised care programs.

## About Palantir Technologies ([www.palantir.com](http://www.palantir.com))

Palantir Technologies is a software company that builds enterprise data platforms for use by organizations with complex and sensitive data environments. From building safer cars and planes to discovering new drugs and combating terrorism, Palantir helps customers across the public, private, and nonprofit sectors transform the way they use their data.

Additional information is available at <https://www.palantir.com>.

---



### **Cautionary Note on Forward-Looking Statements**

Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

For personal use only

## Palantir Introduces Second Cohort of "Foundry for Builders" Start-Ups

*Ten more early-stage companies in industries ranging from digital health to entertainment will be able to leverage Palantir Foundry. This cohort of start-ups is the latest in Palantir's Foundry for Builders initiative, introduced in July to bring Palantir's world-class software platform to early-stage companies.*

October 06, 2021 04:30 PM Eastern Daylight Time

DENVER--(BUSINESS WIRE)--Palantir Technologies Inc. (NYSE:PLTR) announced today it has selected ten additional companies to join its Foundry for Builders initiative, launched in July to support early-stage companies by providing them with the Palantir Foundry platform, helping support their growth.

For Palantir, Foundry for Builders marks a continued expansion of its business to early-stage companies who can fully leverage the end-to-end platform at rapid speed. This next cohort also includes Palantir's first customers in the blockchain and digital health industries.

The Palantir Foundry platform transforms the way organizations run by creating a central operating system for their data that is designed to scale with increasing complexity, meaning it will be able to support these companies as they grow while powering data-driven decision making from the outset.

Under Foundry for Builders, Palantir licenses Foundry to start-ups under a subscription model. The first companies to benefit were connected to Palantir alumni, and Foundry for Builders now includes other early-stage companies. The second cohort of Foundry for Builders companies includes the following:

- [Elementus](#), a New York-based blockchain analytics platform
- [Emyria](#), a Perth-based and Australian Securities Exchange-listed drug development and clinical care company, focusing on novel treatments
- [European Cricket Network](#), a digital media company based in Switzerland dedicated to streaming and promoting European cricket
- [Foodsmart](#), a San Francisco-based digital nutrition and healthy food buying marketplace
- [KatalystDI](#), a Houston-based company dedicated to improving construction through integrating and automating supply chain data
- [mePrism](#), a Los Angeles-based start-up focused on enabling consumers to take control over their data and how it is transacted in the digital marketplace
- [VayuAI](#), a San Francisco-based technology company that operates a platform for optimizing wind farm performance

The companies in this Foundry for Builders cohort are using the platform to establish an internal operating system for their data to spend more time accelerating their unique value proposition.

Palantir Foundry is offered as fully managed SaaS and provides an end-to-end platform that spans from cloud hosting and data integration to flexible analytics, visualization, model-building, operational decision-making, and decision capture. Having these capabilities as part of a single platform eliminates friction and protects against the loss of data history, security, and privacy as users analyze data across siloed technologies.

"The Palantir Foundry platform provides us the ability to aggregate and continuously analyze thousands of previously disconnected data sets, giving us an unprecedented understanding of the construction supply chain. With these powerful tools, our team is focusing on turning integrated data into actionable intelligence for our industry," said Libo Li, the CTO of KatalystDI.

"We're excited to access technology previously reserved for the most established and leading organizations," said European Cricket Network CEO and Founder Daniel Weston, who is using data to grow his digital media company. "We can use Palantir Foundry to ask the right questions of the data, with the best interface and integration tools combined, all in the one place."

In another application of Foundry at an early-stage company, the software will be used by VayuAI, which increases wind farm capacity and production by applying machine learning and physics-based algorithms against massive unstructured wind data. Palantir Foundry will enable VayuAI to provide its customers with data simulations to support the expansion of windfarm output.

Palantir Foundry offers out-of-the-box security and compliance features which allow companies, including these start-ups, to work with sensitive data in accredited environments. The platform is currently being used in over 40 industries and sectors worldwide to deploy AI models to space, strengthen telecommunication network reliability, reduce errors in manufacturing, improve the safety of vehicles, and more.

"We're excited to expand the use of Palantir Foundry to yet another group of hypergrowth startups. These organizations have ambitious goals and timelines – they see building on Foundry as infrastructure as the cheapest and fastest way to market," said Palantir COO Shyam Sankar. "It takes too long and is too risky to manually build solutions from a bag of cloud services. Foundry's software defined data integration and no-code applications mean customers can onboard new customers and develop new apps at a speed and cost that was previously inconceivable."

## About Palantir Technologies

Palantir Technologies is a software company that builds enterprise data platforms for use by organizations with complex and sensitive data environments. From building safer cars and planes, to discovering new drugs and combating terrorism, Palantir helps customers across the public, private, and nonprofit sectors transform the way they use their data. Additional information is available at <https://www.palantir.com>, more details about Foundry for Builders can be found at <https://www.palantir.com/offerings/foundry-for-builders/>.

## Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, Palantir's expectations regarding the terms and benefits of this initiative and related contracts and the expected benefits of our software platforms. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include our ability to meet the unique needs of our customer; the failure of our platforms to satisfy our customer or perform as desired; the frequency or severity of any software and implementation errors; our platforms' reliability; and our customer's ability to modify or terminate the contract. Additional information regarding these and other risks and uncertainties is included in the filings we make with the Securities and Exchange Commission from time to time. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

## Contacts

Lisa Gordon

[media@palantir.com](mailto:media@palantir.com)